Recombinant batroxobin and high-expression-quantity industrial-grade large-scale preparation method thereof

Through genetic engineering technology and multi-step fermentation and culture methods, the stability and efficiency of industrial production of recombinant batrecaps were solved, and a high-expression amount of recombinant batrecaps was obtained, which was used for clinical treatment of thrombotic diseases and met the clinical drug needs. .

CN119020334AActive Publication Date: 2024-11-26BEIJING KANGHAI PHARMACEUTICAL CO LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202411497778.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-25
Publication Date
2024-11-26
Estimated Expiration
2044-10-25

AI Technical Summary

Technical Problem

The prior art is difficult to stably produce high-expression recombinant batrecaps on an industrial scale, and the natural snake venom resources are limited, which makes it difficult to meet the clinical drug demand.

Method used

Using genetic engineering technology, the structural gene sequence of batreczyme is cloned into yeast expression screen to obtain highly expressed engineered bacteria. Multi-step fermentation and induction culture methods are adopted, including glycerol feed and methanol feed induction, combined with Ultrafiltration and purification steps were used to prepare high-titer recombinant batrzys.

Benefits of technology

It has achieved stable acquisition of high expression amounts of recombinant batrecaps on the scale of industrial production, with biological activity comparable to that of natural batrecaps, and can be used for clinical treatment of thrombotic diseases, improving productivity and resource utilization.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
Patent Text Reader

Abstract

The invention relates to recombinant batroxobin and a high-expression-quantity industrial-grade large-scale preparation method thereof. Specifically, the invention relates to a method for preparing recombinant batroxobin, which comprises the following steps: artificially synthesizing a structural gene sequence of batroxobin, and cloning, expressing and screening by using pichia pastoris to obtain a seed solution of high-expression engineering bacteria; the recombinant batroxobin is prepared through fermentation culture according to the following operation: preparation of a primary seed solution, preparation of a secondary seed solution, inoculation and pre-culture in a fermentation tank, glycerol fed-batch culture, methanol fed-batch induction culture and concentration to obtain a fermentation concentrated solution containing the recombinant batroxobin, and the fermentation concentrated solution is optionally purified. The recombinant batroxobin can be clinically used for acute cerebral infarction, is used for improving ischemic symptoms caused by various obliterans (such as thromboangiitis obliterans, deep phlebitis, pulmonary embolism and the like), and is used for improving peripheral and microcirculation disorders (such as sudden deafness and motion sickness). According to the method, the expression quantity of batroxobin is high, and industrial-scale production can be easily realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a recombinant batroxobin and a preparation method thereof. More specifically, the present invention relates to a method for preparing a recombinant protein by using genetic engineering technology and a yeast culture production method, which can easily obtain a high expression amount of recombinant batroxobin on an industrial production scale. The recombinant batroxobin obtained by the method of the present invention has good performance. Background Art

[0002] The types of snake venom thrombin preparations on the market include: Bothrops moojeni ) from snake venom; Ancrod (Viprinex, Arwin) from the venom of the Malaysian red-mouthed pit viper; and Agkistrodon acutus ) Defibrase from snake venom. From 1985 to 2000, multi-component preparations containing snake venom-like thrombins from different snake venom sources were circulated in my country, most of which were called Agkistrodon acutus defibrase. Since 1997, domestic defibrase has replaced Agkistrodon acutus defibrase.

[0003] Since the pit viper has been listed as a national second-level endangered animal, the resources of natural snake venom are extremely limited. In addition, due to well-known reasons, such as the growth environment of the snake, the age of the snake, the season of venom collection and other factors related to the variation of the raw materials of the snake venom, the influence of impurities in the snake venom and the limitation of the output of raw materials, it is extremely difficult to industrially produce this natural batroxobin on a stable scale so that it can be successfully applied in the clinic as a safe, effective and controllable agent, resulting in the current related products being difficult to meet the clinical drug needs. Therefore, it is of great practical significance to use genetic engineering technology to express snake venom thrombin and prepare recombinant batroxobin with biological activity equivalent to that of natural batroxobin.

[0004] Recombinant batroxobin is a single, glycosylated single-chain polypeptide containing 231 amino acids. As a linear glycoprotein-like compound, it contains about 5% carbohydrates and its N-terminal amino acid is valine. Batroxobin is a serine protease secreted by the venom gland. It can release fibrinopeptide A by cleaving 16-Arg-17-Gly in the A(α) chain of fibrinogen and form clots by aggregating fibrin I monomers or Des-AA monomers. However, the specificity of further degradation of fibrinogen varies depending on the species of the enzyme. In contrast to thrombin, it does not affect the function of platelets. Therefore, BX is used to study the final stage of coagulation. Due to its insensitivity to heparin, it can detect fibrinogen polymerization disorders even in the presence of heparin. In addition, it is used to treat thrombotic diseases under the name of defibrase (Pentapharm).

[0005] Japanese scholars first successfully expressed the batroxobin gene in Escherichia coli in 1987 (J. Biol. Chem. 262: 3132-3135). Chinese scholars Li Zhaofa et al. (China Patent Authorization Announcement No. CN100564532C, Patent No. 200610165344.3) expressed biologically active batroxobin protein in yeast. In addition, CN113862246A (Application No. 202111186090.4, Gerritsen) discloses a mixed carbon source induced Pichia pastoris to express recombinant batroxobin and its purification method, including using a continuous fermentation method during the fermentation process, and using a mixed carbon source to induce Pichia pastoris, through glycerol fed culture, methanol / glucose mixed induction culture and other fermentation processes. In addition, CN116334052 (application number 202310399752.9, Shanghai Tengrui) discloses a fermentation method of batroxobin, comprising the following steps: taking the preserved strain and inoculating it into a primary seed culture medium, the formula of the primary seed culture medium is: yeast powder, 1.0%; polypeptone 2.0%; glucose, 2.0%, prepared with purified water and sterilized for use; under sterile conditions, the primary seed liquid is connected to a seed tank containing a secondary culture medium, and the inoculation ratio is 5%-11%. The secondary seed culture medium is formulated as follows: yeast powder, 1.0%; polypeptone 2.0%; glucose, 2.0%, prepared with purified water and sterilized for use; when the OD600 of the secondary seed liquid is between 5-7, in a sterile Under the conditions, 4 ml / L of optimized basic fermentation medium was added to the fermenter, and the secondary seed liquid was transferred into the fermenter under sterile conditions. After culturing for 4 hours, the glycerol feed medium was optimized in the fermenter, and the pH value was adjusted to 6.5, and methanol was induced; the concentration of the glycerol feed medium was 10 ml / L; the supernatant was collected and purified to obtain recombinant batroxobin; the components of the optimized basic fermentation medium were: K2SO4: 0.91%; MgSO4: 0.36%; CaSO4.2H2O: 0.059%; 85% H3PO4: 2.5% V / V; KOH: 0.206%; glycerol: 4%; caproic acid: 0.05%-0.1%; PTM1: 0.4% V / V, casamino acid acids: 0.5%; the optimized glycerol feed medium components: 50% glycerol + 12mL / L PTM1 + 0.5% casamino acids; the methanol induction stage was induced using the optimized methanol induction medium, the optimized methanol induction medium components: (100% methanol + 12mL / L PTM1) 95% + 4.5% sorbitol + 0.5% casamino acids.

[0006] However, the art still awaits new methods for preparing recombinant batroxobin, especially methods for stably obtaining high expression levels of recombinant batroxobin on an industrial production scale. Summary of the invention

[0007] One of the purposes of the present invention is to provide a recombinant batroxobin and a method for preparing the same, in particular to provide a method for stably obtaining a high expression amount of recombinant batroxobin on an industrial production scale. It has been unexpectedly found that by using the method of the present invention, a high expression amount of recombinant batroxobin can be prepared on an industrial production scale. The present invention is completed based on such a discovery.

[0008] To this end, the first aspect of the present invention provides a method for preparing recombinant batroxobin, which comprises artificially synthesizing the structural gene sequence of batroxobin, then using Pichia pastoris to clone and express to obtain the seed liquid of highly expressed engineered bacteria, and then fermenting and culturing to prepare the recombinant batroxobin according to the following operations: (1) Preparation of primary seed solution: The selected engineered bacteria were inoculated into YPD medium and cultured in a shake flask until the OD600 reached 7-9, which was used as the primary seed solution; (2) Preparation of secondary seed solution: The primary seed solution was inoculated into YPD medium and cultured in a shake flask until the OD600 reached 7-9 to serve as the secondary seed solution; (3) Fermentation tank inoculation and pre-culture: The secondary seed liquid was inoculated into the fermentation medium of the fermentation tank, and cultured under the initial culture conditions of 30°C, pH 5.8-6.2, rotation speed 150-220 rpm, and air ventilation volume 0.8-1.2 vvm. During the fermentation process, the rotation speed and air ventilation volume were gradually increased, and the dissolved oxygen was controlled in the range of 15-25% until the rotation speed was increased to 650-750 rpm and the air ventilation volume was increased to 1.8-2.5 vvm. Then, the culture was continued until the carbon source was exhausted, and then glycerol fed-batch culture was carried out; (4) Glycerol feeding culture: Start feeding by adding 50% glycerol containing 10-14 ml / L of PTM1 solution at a rate of 5 ml / h / L. Gradually increase the feeding rate to 45-55 ml / h / L within 30 min. During this period, adjust the rotation speed and air ventilation volume to control the dissolved oxygen in the range of 15-25%. Continue to culture until the wet weight of the bacteria reaches the range of 250-270 g / L, and then enter the next methanol feeding; (5) Methanol feeding induction culture: the fermentation broth temperature was lowered to 25°C, the pH was adjusted to 2.8-3.2, and methanol containing 10-14 ml / L of PTM1 solution was added dropwise at a rate of 2.8-3.5 ml / h / L. The methanol feeding rate was maintained until the end of the fermentation. During this period, the rotation speed and air ventilation volume were adjusted to control the dissolved oxygen in the range of 15-25%. After the rotation speed and air ventilation volume reached the maximum, oxygen was introduced to achieve a maximum ventilation volume of 0.28-0.32 vvm. After the fermentation was completed, the fermentation broth was centrifuged and the supernatant was collected. (6) The centrifuged supernatant is ultrafiltered using an ultrafiltration membrane with a molecular weight cutoff of 10K, and concentrated until the volume of the liquid above the membrane is 1 / 10 of the volume of the initial supernatant to obtain a fermentation concentrate containing recombinant batroxobin, which is optionally purified.

[0009] According to the method of the first aspect of the present invention, the titer of the batroxobin fermentation concentrate obtained in step (6) is greater than 40BU / ml, for example, greater than 50BU / ml, for example, greater than 60BU / ml, for example, greater than 70BU / ml, for example, greater than 80BU / ml.

[0010] According to the method of the first aspect of the present invention, the YPD medium used is composed of: 1% peptone, 0.5% yeast extract, 2% glucose, water, and hydrochloric acid or sodium hydroxide to adjust the pH to 6.0±0.2.

[0011] According to the method of the first aspect of the present invention, the composition of the fermentation medium used is: 13 ml / L 85% phosphoric acid, 0.46 g / L calcium sulfate dihydrate, 9.1 g / L potassium sulfate, 7.46 g / L magnesium sulfate heptahydrate, 2.06 g / L potassium hydroxide, 30.0 g / L glycerol, 4.35 ml / L PTM1 solution, and the balance water.

[0012] According to the method of the first aspect of the present invention, the composition of the PTM1 solution used is: 6 g / L copper sulfate, 0.088 g / L sodium iodide, 3 g / L manganese sulfate, 0.2 g / L sodium molybdate, 0.02 g / L boric acid, 0.5 g / L cobalt chloride, 20 g / L zinc chloride, 65 g / L ferrous sulfate, 0.2 g / L biotin, and the remainder water.

[0013] According to the method of the first aspect of the present invention, the composition of the PTM1 solution used is: 6 g / L copper sulfate, 0.088 g / L sodium iodide, 3 g / L manganese sulfate, 0.2 g / L sodium molybdate, 0.02 g / L boric acid, 0.5 g / L cobalt chloride, 20 g / L zinc chloride, 65 g / L ferrous sulfate, 0.2 g / L biotin, 1.2 g / L inositol, 2.5 g / L calcium pantothenate, and the balance water.

[0014] According to the method of the first aspect of the present invention, when the structural gene sequence of batroxobin is artificially synthesized, in order to allow the synthesized target gene to be recombined into the yeast secretory expression vector pPICZα, an Xho I restriction site is added to the 5′ end of the gene, and a termination codon TAATGA and a SacII restriction site are added to the 3′ end of the gene.

[0015] According to the method of the first aspect of the present invention, when the structural gene sequence of batroxobin is artificially synthesized, the synthesized target gene and pPICZα vector are double-digested by Xho I and SacII, electrophoresed, recovered, and the target gene is recombined into pPICZα, transformed into Escherichia coli Top10F', and screened. Escherichia coli Top10F' transformed with pPICZα is cultured on an LB medium plate supplemented with Zeocin, a single colony is picked, cultured in a liquid medium, the plasmid is extracted, and double-digested with Xho I and SacII, α-factor priming and 3'AOX1 priming PCR are performed, showing that pPICZα contains the target gene and can be used to transform Pichia pastoris.

[0016] According to the method of the first aspect of the present invention, when the structural gene sequence of batroxobin is artificially synthesized, the LB medium with Zeocin added is composed of: 1% tryptone, 0.5% yeast extract, 0.5% sodium chloride, 1.5% agar, the pH value is adjusted to 7.0, autoclaved, and 25µg / mg of zeocin (bleomycin) is added during plating. According to the method of the first aspect of the present invention, when the structural gene sequence of batroxobin is artificially synthesized, the liquid culture medium is composed of: 1% tryptone, 0.5% yeast extract, 0.5% sodium chloride, the pH value is adjusted to 7.0, and autoclaved.

[0017] According to the method of the first aspect of the present invention, when Pichia pastoris is used for cloning expression screening to obtain a seed solution of highly expressing engineered bacteria, pPICZα-Bg is linearized with the DNA restriction endonuclease SacI-HF™, and a multi-copy Pichia pastoris expression kit of Gibco is used to prepare a yeast host competent state and transform it according to the method described in the kit. The transformed cells are spread on YPDZ medium and grown at 30°C for 4 to 5 days to produce single colonies. Clones with large and full colonies are selected for expression screening, and highly expressing engineered bacteria are screened out in test tubes and inoculated into shake flasks for proliferation as seed solution of engineered bacteria.

[0018] According to the method of the first aspect of the present invention, the YPDZ medium is composed of: 1% yeast extract, 2% peptone, 2% glucose, 2% agar, and 200 µg / ml bleomycin.

[0019] According to the method of the first aspect of the present invention, in step (1) of preparing the primary seed solution: the screened high-expression engineered bacteria are inoculated at a 1‰ inoculation rate into a (e.g. 2L) shake flask containing (e.g. 500ml) YPD medium, and cultured at 30°C and 250rpm until the OD600 reaches 7-9, as the primary seed solution.

[0020] According to the method of the first aspect of the present invention, in the step (2) of preparing the secondary seed solution: the primary seed solution is inoculated at a 10% inoculation amount into a (e.g. 4L) shake flask containing (e.g. 3, each containing 1000 ml) YPD medium, and cultured in the shake flask at 30°C and 250 rpm until the OD600 reaches 7-9, as the secondary seed solution.

[0021] According to the method of the first aspect of the present invention, in step (3), when the secondary seed liquid is inoculated into the fermentation medium of the fermenter, the volume ratio of the secondary seed liquid to the fermentation medium is 1:8-12.

[0022] According to the method of the first aspect of the present invention, in step (5), while maintaining the methanol feeding rate until the end of fermentation, samples are taken at regular intervals (for example, every 5 hours) to detect the expression level of recombinant batroxobin in the supernatant, and when the expression level no longer increases, it is regarded as the fermentation end point.

[0023] As a commonly used anticoagulant, the natural batroxobin product batroxobin injection has the following clinical indications: In view of the fact that the recombinant batroxobin obtained in the present invention also exhibits biological activity comparable to that of the natural batroxobin, the second aspect of the present invention provides the use of the recombinant batroxobin prepared by the method described in any one of the first aspects of the present invention in the preparation of drugs for the following medical indications: For acute cerebral infarction; Used to improve ischemic symptoms caused by various occlusive vascular diseases (such as thromboangiitis obliterans, deep phlebitis, pulmonary embolism, etc.); Used to improve peripheral and microcirculation disorders (such as sudden deafness and motion sickness).

[0024] In the method steps described in the present invention, although the specific steps described therein are different from the method steps in other parts of this document in some details or language descriptions, those skilled in the art can fully summarize the above-mentioned method steps based on the detailed disclosure of the full text of the present invention.

[0025] Any embodiment of any aspect of the present invention can be combined with any other embodiment of the present invention, as long as they do not conflict. In addition, in any embodiment of any aspect of the present invention, any technical feature can be applied to the technical feature in any other embodiment of the present invention, as long as they do not conflict.

[0026] The present invention is further described below.

[0027] All documents cited in the present invention are incorporated herein by reference in their entirety, and if the meanings expressed in these documents are inconsistent with the present invention, the description of the present invention shall prevail. In addition, the various terms and phrases used in the present invention have the general meanings known to those skilled in the art. Even so, the present invention still hopes to provide a more detailed description and explanation of these terms and phrases. If the terms and phrases mentioned are inconsistent with the known meanings, the meanings expressed in the present invention shall prevail.

[0028] The commercial product of natural batroxobin is called Batroxo-purified thrombin, which is a single-chain glycoprotein. It is a serine proteolytic enzyme isolated from the venom of the American lancehead pit viper, and is a glycopeptide composed of 231 amino acids. Because of its functions of decomposing fibrinogen and promoting the release of tissue-type plasminogen activator, the gene of the enzyme has been cloned and recombinantly expressed in the Pichia yeast system, and some of its biochemical properties have also been studied. It can specifically cleave the Arg16-Gly17 bond in the fibrinogen chain to release fibrinopeptide A. The enzyme does not activate factors, thereby converting fibrinogen in the blood into loose soft clots, which are easily degraded by hydrolases, resulting in a decrease in the concentration of fibrinogen in the blood, and playing the role of defibrase. Based on these biochemical characteristics, natural batroxobin has been successfully developed into a defibrinogen drug, which is used in the clinical treatment of thrombotic diseases such as deep vein thrombosis, myocardial infarction, pulmonary embolism, and acute ischemic stroke.

[0029] The natural batroxobin used in clinical practice is administered by intravenous drip, presenting a one-compartment model, which can effectively reduce the content of fibrinogen in the blood, reduce the viscosity of whole blood and plasma, reduce vascular resistance, and increase blood flow. Healthy adults were given intravenous drips, 10BU each time, once every other day, for a total of three times, and the half-life was measured: the first dose was 5.9 hours; the second dose was 3.0 hours; the third dose was 2.8 hours. Compared with the initial administration, the half-life after the second dose shortened with the decrease in fibrinogen concentration, and the half-life of the administration after the fibrinogen concentration was restored was the same as the initial administration. Animal experiments showed that Wistar rats were intravenously injected with 125I-batroxobin to examine the distribution in the body. The results showed that it was distributed higher in the liver and kidneys; it was also distributed in the blood, spleen, and lungs; it was distributed lower in the brain, fat, and muscle; there was no significant distribution difference between males and females; the fetus had a transient liver dysfunction phenomenon. After intravenous administration (10BU) to healthy adults, most of the metabolites were excreted in the urine.

[0030] The present invention adopts a genetic engineering method to prepare genetically engineered recombinant batroxobin with biological activity equivalent to that of natural batroxobin on an industrial scale and at a high expression level. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1: SDS electrophoresis of the recombinant batroxobin obtained in the present invention. DETAILED DESCRIPTION

[0032] The present invention can be further described by the following examples, however, the scope of the present invention is not limited to the following examples. It will be appreciated by those skilled in the art that various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention. The present invention provides general and / or specific descriptions of the materials and test methods used in the test. Although many materials and operating methods used to achieve the purpose of the present invention are well known in the art, the present invention is still described in as much detail as possible herein. The following examples further illustrate the present invention, rather than limiting the present invention.

[0033] Natural batroxobin: The natural batroxobin preparation batroxobin injection (Dongli Difu, national medicine standard H20030295, 0.5ml: 5BU, Tobixi) was purchased from commercial sources, and its remaining effective period when used for comparative tests in the present invention was greater than 13 months.

[0034] Example 1: Structural gene sequence of artificially synthesized batroxobin Methods for artificially synthesizing the structural gene sequence of batroxobin are known, for example, see Itoh, N., Tanaka, N., Mihashi, S. and Yamashina, I.; Molecular cloning and sequence analysis of cDNA for batroxobin, a thrombin-like snake venom enzyme; J. Biol. Chem. 262(7), 3132-3135 (1987). The Genbank database also contains the nucleic acid sequence of batroxobin in detail (GenBank: J02684.1, see https: / / www.ncbi.nlm.nih.gov / nuccore / J02684.1 for details, the present invention uses this sequence as the target gene to prepare recombinant batroxobin). In addition, the Genbank database also contains a detailed protein sequence of the batroxobin precursor (GenBank: AAA48552.1, see https: / / www.ncbi.nlm.nih.gov / protein / 211024 for details). The batroxobin precursor consists of 255 amino acids, of which amino acids 1 to 18 are signal peptides, and amino acids 25 to 255, a total of 231 amino acids, are the batroxobin protein sequence.

[0035] The structural gene sequence of batroxobin was artificially synthesized by a method commonly used in the art, for example, with reference to the method described in CN102258483B (CN2010101577855). In order to recombinant the synthesized target gene into the yeast secretory expression vector pPICZα, an Xho I restriction site was added to the 5′ end of the gene, and a stop codon TAATGA and a SacII restriction site were added to the 3′ end of the gene.

[0036] The synthesized target gene and pPICZα vector were double-digested with Xho I and SacII, electrophoresed, recovered, and the target gene was recombined into pPICZα, transformed into Escherichia coli Top10F', and screened. Escherichia coli Top10F' transformed with pPICZα was cultured on an LB medium plate supplemented with Zeocin, a single colony was picked, cultured in a liquid medium, and the plasmid was extracted. Double-digestion detection with Xho I and SacII, α-factor priming and 3'AOX1 priming PCR detection were performed, showing that pPICZα contained the target gene, which can be used to transform Pichia pastoris, for example, to transform Pichia pastoris X-33 glycerol stock (Pichia Pastoris X-33 Yeast Glycerol Stock, Biyuntian), KM71H Pichia pastoris (NTCC® Type Culture Collection Center), Pichia pastoris GS115 glycerol stock (Biyuntian), etc., and GS115 is used in the present invention unless otherwise specified. LB medium: 1% tryptone, 0.5% yeast extract, 0.5% sodium chloride, 1.5% agar, adjust pH to 7.0, autoclave, add 25µg / mg zeocin (bleomycin) when plating. Liquid medium: 1% tryptone, 0.5% yeast extract, 0.5% sodium chloride, adjust pH to 7.0, autoclave.

[0037] Example 2: Cloning and expression screening of high-expression engineering bacteria pPICZα-Bg was linearized with DNA restriction endonuclease SacI-HF™ (purchased from New England Biolabs, #R3156) and expressed using Gibco's Multi-Copy Pichia Expression Kit. Kit, which contains 20µg each of pPIC3.5K, pPIC9K and pAO815 vectors, Pichia pastoris strain GS115 (his4), KM71 (arg4-his4-aox1::arg4), control strain GS115 albumin, control strain GS115β-gal, Spheroplast transformation kit, and 2µg each of 5´aox1, 3´AOX2 and α-factor sequencing primers, which can be used to produce and screen Pichia pastoris with more than one copy of the target gene), prepare yeast host competent state and transform according to the method described in its instructions, spread the transformed cells on YPDZ medium (which is prepared by 1% yeast extract, 2% peptone, 2% glucose, 2% agar, and 200µg / ml bleomycin), grow at 30°C for 4-5 days to produce single colonies, select clones with large and full colonies for expression screening, and screen out highly expressed engineered bacteria in test tubes and inoculate them into shake flasks for proliferation as engineered bacteria seed liquid.

[0038] Example 3: Preparation of recombinant batroxobin The preparation method of recombinant batroxobin has been recorded in the art, for example, see CN116286408A (202111502192.2). In this embodiment, recombinant batroxobin is prepared according to the following operation.

[0039] (1) Preparation of primary seed solution: The high-expression engineered bacteria selected in Example 2 were inoculated at a 1‰ inoculum into a 2 L shake flask containing 500 ml of YPD medium, and cultured at 30° C. and 250 rpm until the OD600 reached 7-9, which was used as the primary seed solution; (2) Preparation of secondary seed solution: 10% of the primary seed solution was inoculated into three 4 L shake flasks each containing 1000 ml of YPD medium, and cultured at 30°C and 250 rpm until the OD600 reached 7-9. This was used as the secondary seed solution.

[0040] (3) Fermentation tank inoculation and pre-culture: 2 L of secondary seed liquid was inoculated into a 30 L fermentation tank containing 20 L of fermentation medium for fermentation. The initial culture conditions were 30 °C, pH 6.0, rotation speed 200 rpm, and air ventilation volume 1 vvm. During the fermentation process, the rotation speed and air ventilation volume were gradually increased, and the dissolved oxygen was controlled within the range of 15-25% until the rotation speed was increased to 750 rpm and the air ventilation volume was increased to 2 vvm. The culture was then continued until the carbon source was exhausted (about 8.6 h, the dissolved oxygen increased significantly), and then glycerol fed-batch culture was performed. (4) Glycerol feeding culture: Start feeding by adding 50% glycerol containing 12 ml / L of PTM1 solution at a rate of 5 ml / h / L. Gradually increase the feeding rate to 50 ml / h / L within 30 min. During this period, adjust the rotation speed and air ventilation volume to control the dissolved oxygen in the range of 15-25%. Continue to culture for 6.5 h until the wet weight of the bacteria reaches 250-270 g / L (265 g / L), and the liquid feed is about 23 L, then enter the next methanol feeding; (5) Methanol feeding induction culture: the fermentation broth temperature was lowered to 25°C and the pH was adjusted to 3.0. Methanol containing 12 ml / L of PTM1 solution was added dropwise at a rate of 3 ml / h / L. The methanol feeding rate was maintained until the end of the fermentation (the expression level of recombinant batroxobin in the supernatant was detected every 5 hours. When the expression level no longer increased, it was regarded as the end point of the fermentation, which took 46 hours). During this period, the rotation speed and air ventilation volume were adjusted to control the dissolved oxygen in the range of 15-25%. After the rotation speed and air ventilation volume reached the maximum, oxygen was introduced (maximum ventilation volume 0.3 vvm); after the fermentation was completed, the fermentation broth was centrifuged and about 24 L of supernatant was collected; (6) The centrifuged supernatant was ultrafiltered using an ultrafiltration membrane with a molecular weight cutoff of 10K and concentrated until the volume of the liquid above the membrane was 1 / 10 of the volume of the initial supernatant, thereby obtaining 2375 ml of fermentation concentrate containing recombinant batroxobin.

[0041] Using the method of Example 4, it was measured that the potency of the concentrated solution of batroxobin fermentation obtained from step (3) to step (6) was 54.6BU / ml and the total potency was 129.7kBU; if it is packaged into glass bottles with reference to the specification of 5BU / ml per vial of the commercially available product, without considering the subsequent purification loss, it can theoretically be used to package 26,000 vials of recombinant batroxobin injection; even if the subsequent purification loss of 50% is considered, this recombinant batroxobin harvest can also be used to package 13,000 vials of the final product recombinant batroxobin injection in the later preparation process, indicating that the method of the present invention can be used for the preparation of recombinant batroxobin on an industrial scale.

[0042] The above YPD medium consists of: 1% peptone, 0.5% yeast extract, 2% glucose, water, and hydrochloric acid or sodium hydroxide to adjust the pH to 6.0 ± 0.2, prepared according to the usual method; The composition of the above fermentation medium: 85% phosphoric acid 13ml / L, calcium sulfate dihydrate 0.46g / L, potassium sulfate 9.1g / L, magnesium sulfate heptahydrate 7.46g / L, potassium hydroxide 2.06g / L, glycerol 30.0g / L, PTM1 solution 4.35ml / L, balance water, prepared according to the usual method; The above PTM1 solution consists of: 6 g / L copper sulfate, 0.088 g / L sodium iodide, 3 g / L manganese sulfate, 0.2 g / L sodium molybdate, 0.02 g / L boric acid, 0.5 g / L cobalt chloride, 20 g / L zinc chloride, 65 g / L ferrous sulfate, 0.2 g / L biotin, and the balance water; prepared according to the conventional method.

[0043] Example 4: Determination of the potency of batroxobin Referring to the method for determining the potency of batroxobin in the national drug standard of commercially available batroxobin injection, the potency of the batroxobin fermentation concentrate obtained in step (6) of each embodiment of the present invention was determined, and the specific method is as follows.

[0044] (1) Test solution preparation: Dilution: Take 0.2g partially hydrolyzed gelatin, 1.0g dextran 70, 0.3g chlorobutanol, dissolve and dilute to 100ml with tris(hydroxymethyl)aminomethane buffer, shake well, and obtain; Partially hydrolyzed gelatin: Take 50g of refined gelatin and 2.5g of calcium chloride, add 450ml of water, heat on a 50℃ water bath until dissolved, slowly adjust the pH value to 3.0 with phosphoric acid, and then place it at 121℃, 1.1kg / cm 2 Heat in an autoclave for 90 minutes, take out and cool to room temperature, adjust the pH to 6.5 with 1 mol / L sodium hydroxide solution, let stand, take the supernatant and filter it with a 0.45µm filter membrane, freeze-dry the filtrate and set aside; Tris(hydroxymethyl)aminomethane buffer solution: Take 18.17g of Tris(hydroxymethyl)aminomethane and 0.8g of sodium chloride, add 800ml of water to dissolve, adjust the pH value to 7.2 with 1mol / L hydrochloric acid solution, add water to 1000ml, shake well, and obtain; Fibrinogen solution: Take 0.2g of partially hydrolyzed gelatin, 1.0g of dextran 70, and 0.3g of chlorobutanol, dissolve them in water, add water to 100ml, shake well, and take another 8mg of bovine fibrinogen and dissolve it in 2ml of the above solution. Prepare it before use.

[0045] (2) Preparation of standard curve: Take an appropriate amount of batroxobin standard, weigh it accurately, and dilute it with diluent to prepare standard solutions containing 2.0, 4.0, 6.0, 8.0, and 10.0 BU per ml; Take 0.2 ml of fibrinogen solution and place it in 5 small test tubes respectively. Place the test tubes in a 37℃ water bath and keep warm for 3 minutes. Accurately measure 0.1 ml of the preheated standard solution and quickly add it to each test tube of fibrinogen solution. Start timing, shake well immediately, place in a 37°C water bath, and record the coagulation time. The standard solution of each concentration was measured 5 times, and the average value and standard deviation were calculated (when the standard deviation was greater than 3.0 seconds, it was necessary to measure again); a standard curve was drawn with the logarithm of the concentration of the standard solution as the abscissa and the logarithm of the average value of the coagulation time as the ordinate.

[0046] (3) Determination: For commercially available batroxobin injection (Bao Ling Di Fu, 0.5ml:5BU), accurately measure 5ml and place it in a 10ml volumetric flask, dilute to the mark with diluent, shake well, and use it as the test solution (concentration is about 5BU / ml); For the batroxobin fermentation concentrate obtained in step (6) of Example 3 and other examples, its approximate potency is determined by preliminary experiments, and then an appropriate amount is accurately measured and added to a volumetric flask, and diluted to the scale with a diluent to prepare a solution with a concentration of about 5BU / ml as the test solution; After preheating the test solution in a 37°C water bath, accurately measure 0.1 ml and add it to a test tube containing 0.2 ml of fibrinogen solution according to the method under "(2) Preparation of standard curve". Measure the clotting time and calculate the average value and standard deviation of 5 times (the standard deviation is the same as the preparation requirements of the standard curve). Calculate the potency of the test sample on the standard curve.

[0047] The potency of the commercially available batroxobin injection was determined to be 11.26 BU / ml, indicating that the method of the present invention is reliable when verified using commercially available products.

[0048] Example 5: Preparation of recombinant batroxobin This example mainly refers to Example 3 of the present invention, but the operating parameters of the preparation process are appropriately modified.

[0049] (1) Preparation of primary seed solution: The high-expression engineered bacteria selected in Example 2 were inoculated at a 1‰ inoculum into a 2 L shake flask containing 500 ml of YPD medium, and cultured at 30° C. and 250 rpm until the OD600 reached 7-9, which was used as the primary seed solution; (2) Preparation of secondary seed solution: 10% of the primary seed solution was inoculated into three 4 L shake flasks each containing 1000 ml of YPD medium, and cultured at 30°C and 250 rpm until the OD600 reached 7-9. This was used as the secondary seed solution.

[0050] (3) Fermentation tank inoculation and pre-culture: 2 L of secondary seed liquid was inoculated into a 30 L fermentation tank containing 20 L of fermentation medium for fermentation. The initial culture conditions were 30 °C, pH 6.2, rotation speed 150 rpm, and air ventilation volume 1.2 vvm. During the fermentation process, the rotation speed and air ventilation volume were gradually increased, and the dissolved oxygen was controlled within the range of 15-25% until the rotation speed was increased to 700 rpm and the air ventilation volume was increased to 2.5 vvm. The culture was then continued until the carbon source was exhausted (about 8.3 h, the dissolved oxygen increased significantly), and then glycerol fed-batch culture was performed. (4) Glycerol feeding culture: Start feeding by adding 50% glycerol containing 10 ml / L of PTM1 solution at a rate of 5 ml / h / L. Gradually increase the feeding rate to 55 ml / h / L within 30 min. During this period, adjust the rotation speed and air ventilation volume to control the dissolved oxygen in the range of 15-25%. Continue to culture for 6.3 h until the wet weight of the bacteria reaches the range of 250-270 g / L (257 g / L), and the liquid feed is about 23 L, then enter the next methanol feeding; (5) Methanol feeding induction culture: the fermentation broth temperature was lowered to 25°C, the pH was adjusted to 3.2, and methanol containing 14 ml / L of PTM1 solution was added dropwise at a rate of 3.5 ml / h / L. The methanol feeding rate was maintained until the end of the fermentation (the expression level of the recombinant batroxobin in the supernatant was detected every 5 hours, and the fermentation end point was taken when the expression level no longer increased, which took 45 hours). During this period, the rotation speed and air ventilation volume were adjusted to control the dissolved oxygen in the range of 15-25%, and oxygen was introduced after the rotation speed and air ventilation volume reached the maximum (the maximum ventilation volume was 0.32 vvm); after the fermentation was completed, the fermentation broth was centrifuged and about 24 L of supernatant was collected; (6) The centrifuged supernatant was ultrafiltered using an ultrafiltration membrane with a molecular weight cutoff of 10K and concentrated until the volume of the liquid above the membrane was 1 / 10 of the volume of the initial supernatant, thereby obtaining 2426 ml of fermentation concentrate containing recombinant batroxobin.

[0051] Using the method of Example 4, the titer of the batroxobin fermentation concentrate obtained from step (3) to step (6) was measured to be 51.4 BU / ml and the total titer was 124.7 kBU. The YPD medium, fermentation medium and PTM1 solution used in this example were the same as those in Example 3.

[0052] Example 6: Preparation of recombinant batroxobin This example mainly refers to Example 3 of the present invention, but the operating parameters of the preparation process are appropriately modified.

[0053] (1) Preparation of primary seed solution: The high-expression engineered bacteria selected in Example 2 were inoculated at a 1‰ inoculum into a 2 L shake flask containing 500 ml of YPD medium, and cultured at 30° C. and 250 rpm until the OD600 reached 7-9, which was used as the primary seed solution; (2) Preparation of secondary seed solution: 10% of the primary seed solution was inoculated into three 4 L shake flasks each containing 1000 ml of YPD medium, and cultured at 30°C and 250 rpm until the OD600 reached 7-9. This was used as the secondary seed solution.

[0054] (3) Fermentation tank inoculation and pre-culture: 2 L of secondary seed liquid was inoculated into a 30 L fermentation tank containing 20 L of fermentation medium for fermentation. The initial culture conditions were 30 °C, pH 5.8, rotation speed 220 rpm, and air ventilation volume 0.8 vvm. During the fermentation process, the rotation speed and air ventilation volume were gradually increased, and the dissolved oxygen was controlled within the range of 15-25% until the rotation speed was increased to 650 rpm and the air ventilation volume was increased to 1.8 vvm. The culture was then continued until the carbon source was exhausted (about 9.1 h, the dissolved oxygen increased significantly), and then glycerol fed-batch culture was performed. (4) Glycerol feeding culture: Start feeding by adding 50% glycerol containing 14 ml / L of PTM1 solution at a rate of 5 ml / h / L. Gradually increase the feeding rate to 45 ml / h / L within 30 min. During this period, adjust the rotation speed and air ventilation volume to control the dissolved oxygen in the range of 15-25%. Continue to culture for 7 h until the wet weight of the bacteria reaches 250-270 g / L (268 g / L), and the liquid feed is about 23 L, then enter the next methanol feeding; (5) Methanol feeding induction culture: the fermentation broth temperature was lowered to 25°C, the pH was adjusted to 2.8, and methanol containing 10 ml / L of PTM1 solution was added dropwise at a rate of 2.8 ml / h / L. The methanol feeding rate was maintained until the end of the fermentation (the expression level of recombinant batroxobin in the supernatant was detected every 5 hours, and the fermentation end point was taken when the expression level no longer increased, which took 49 hours). During this period, the rotation speed and air ventilation volume were adjusted to control the dissolved oxygen in the range of 15-25%, and oxygen was introduced after the rotation speed and air ventilation volume reached the maximum (the maximum ventilation volume was 0.28 vvm); after the fermentation was completed, the fermentation broth was centrifuged and about 24 L of supernatant was collected; (6) The centrifuged supernatant was ultrafiltered using an ultrafiltration membrane with a molecular weight cutoff of 10K and concentrated until the volume of the liquid above the membrane was 1 / 10 of the volume of the initial supernatant, thereby obtaining 2393 ml of fermentation concentrate containing recombinant batroxobin.

[0055] Using the method of Example 4, the titer of the batroxobin fermentation concentrate obtained from step (3) to step (6) was measured to be 56.6 BU / ml and the total titer was 135.4 kBU. The YPD medium, fermentation medium and PTM1 solution used in this example were the same as those in Example 3.

[0056] Example 7: Preparation of recombinant batroxobin This example mainly refers to Example 3 of the present invention, but the composition of the PTM1 solution is appropriately modified.

[0057] (1) Preparation of primary seed solution: The high-expression engineered bacteria selected in Example 2 were inoculated at a 1‰ inoculum into a 2 L shake flask containing 500 ml of YPD medium, and cultured at 30° C. and 250 rpm until the OD600 reached 7-9, which was used as the primary seed solution; (2) Preparation of secondary seed solution: 10% of the primary seed solution was inoculated into three 4 L shake flasks each containing 1000 ml of YPD medium, and cultured at 30°C and 250 rpm until the OD600 reached 7-9. This was used as the secondary seed solution.

[0058] (3) Fermentation tank inoculation and pre-culture: 2 L of secondary seed liquid was inoculated into a 30 L fermentation tank containing 20 L of fermentation medium for fermentation. The initial culture conditions were 30 °C, pH 6.0, rotation speed 200 rpm, and air ventilation volume 1 vvm. During the fermentation process, the rotation speed and air ventilation volume were gradually increased, and the dissolved oxygen was controlled within the range of 15-25% until the rotation speed was increased to 750 rpm and the air ventilation volume was increased to 2 vvm. The culture was then continued until the carbon source was exhausted (about 8.4 h, the dissolved oxygen increased significantly), and then glycerol fed-batch culture was performed. (4) Glycerol feeding culture: Start feeding by adding 50% glycerol containing 12 ml / L of PTM1 solution at a rate of 5 ml / h / L. Gradually increase the feeding rate to 50 ml / h / L within 30 min. During this period, adjust the rotation speed and air ventilation volume to control the dissolved oxygen in the range of 15-25%. Continue to culture for 6.5 h until the wet weight of the bacteria reaches the range of 250-270 g / L (261 g / L), and the liquid feed is about 23 L, then enter the next methanol feeding; (5) Methanol feeding induction culture: the fermentation broth temperature was lowered to 25°C and the pH was adjusted to 3.0. Methanol containing 12 ml / L of PTM1 solution was added dropwise at a rate of 3 ml / h / L. The methanol feeding rate was maintained until the end of the fermentation (the expression level of recombinant batroxobin in the supernatant was detected every 5 hours. When the expression level no longer increased, it was regarded as the end point of the fermentation, which took 46 hours). During this period, the rotation speed and air ventilation volume were adjusted to control the dissolved oxygen in the range of 15-25%. After the rotation speed and air ventilation volume reached the maximum, oxygen was introduced (maximum ventilation volume 0.3 vvm); after the fermentation was completed, the fermentation broth was centrifuged and about 24 L of supernatant was collected; (6) The centrifuged supernatant was ultrafiltered using an ultrafiltration membrane with a molecular weight cutoff of 10K and concentrated until the volume of the liquid above the membrane was 1 / 10 of the initial supernatant volume, thereby obtaining 2411 ml of fermentation concentrate containing recombinant batroxobin.

[0059] The YPD medium used in this example is composed of 1% peptone, 0.5% yeast extract, 2% glucose, water, and hydrochloric acid or sodium hydroxide to adjust the pH to 6.0±0.2, and is prepared according to the usual method; The composition of the fermentation medium used in this example: 85% phosphoric acid 13ml / L, calcium sulfate dihydrate 0.46g / L, potassium sulfate 9.1g / L, magnesium sulfate heptahydrate 7.46g / L, potassium hydroxide 2.06g / L, glycerol 30.0g / L, PTM1 solution 4.35ml / L, balance water, prepared according to the usual method; The PTM1 solution used in this example consists of 6 g / L copper sulfate, 0.088 g / L sodium iodide, 3 g / L manganese sulfate, 0.2 g / L sodium molybdate, 0.02 g / L boric acid, 0.5 g / L cobalt chloride, 20 g / L zinc chloride, 65 g / L ferrous sulfate, 0.2 g / L biotin, 1.2 g / L inositol, 2.5 g / L calcium pantothenate, and the balance water; it is prepared according to conventional methods.

[0060] Using the method of Example 4, it was measured that the potency of the concentrated solution of batroxobin fermentation obtained from step (3) to step (6) was 87.3BU / ml and the total potency was 210.5kBU; if it is packaged into glass bottles with reference to the specification of 5BU / ml per vial of the commercially available product, without considering the subsequent purification loss, it can theoretically be used to package 42,000 vials of recombinant batroxobin injection; even if the subsequent purification loss of 50% is considered, this recombinant batroxobin harvest can also be used to package 21,000 vials of the final product recombinant batroxobin injection in the later preparation process, indicating that the method of the present invention can be used for the preparation of recombinant batroxobin on an industrial scale.

[0061] Embodiment 8: The preparation process and operation parameters of Example 5 are referred to, but the YPD medium, fermentation medium, and PTM1 solution used are the same as those of Example 7, including the composition of the PTM1 solution used: 6 g / L copper sulfate, 0.088 g / L sodium iodide, 3 g / L manganese sulfate, 0.2 g / L sodium molybdate, 0.02 g / L boric acid, 0.5 g / L cobalt chloride, 20 g / L zinc chloride, 65 g / L ferrous sulfate, 0.2 g / L biotin, 1.2 g / L inositol, 2.5 g / L calcium pantothenate, and the balance water; prepared according to the conventional method. In step (6) of this Example 8, the volume of the batroxobin fermentation concentrate obtained was 2368 ml, the titer was 91.7 BU / ml, and the total titer was 217.1 kBU.

[0062] Embodiment 9:The preparation process and operation parameters of Example 6 are referred to, but the YPD medium, fermentation medium, and PTM1 solution used are the same as those of Example 7, including the composition of the PTM1 solution used: 6 g / L copper sulfate, 0.088 g / L sodium iodide, 3 g / L manganese sulfate, 0.2 g / L sodium molybdate, 0.02 g / L boric acid, 0.5 g / L cobalt chloride, 20 g / L zinc chloride, 65 g / L ferrous sulfate, 0.2 g / L biotin, 1.2 g / L inositol, 2.5 g / L calcium pantothenate, and the balance water; prepared according to the usual method. In step (6) of this Example 9, the volume of the batroxobin fermentation concentrate obtained was 2403 ml, the titer was 88.6 BU / ml, and the total titer was 212.9 kBU. According to the results of Examples 7 to 9, compared with Examples 3 and 5 to 6 of the present invention, it was unexpectedly found that after adding appropriate amounts of inositol and calcium pantothenate to the PTM1 solution used in steps (3) to (6), the titer of batroxobin in the fermentation concentrate can be significantly increased, and the expression level of recombinant batroxobin in the fermentation concentrate can be significantly increased.

[0063] The batroxobin fermentation concentrate obtained in step (6) of Example 3 and Examples 5 to 9 can be further purified by hydrophobic column chromatography, ion exchange column chromatography, gel affinity column chromatography and / or reverse phase liquid chromatography and other commonly used methods in the art to obtain a glycoprotein recombinant batroxobin of desired purity and meeting pharmaceutical requirements. In another experiment, the inventors took an appropriate amount of the batroxobin fermentation concentrate obtained in step (6) of Example 7, and referred to the method of Example 4 of CN108559740B (Chinese Patent No. 2018104523815) to purify it using gel affinity column chromatography and reverse phase liquid chromatography, and the glycoprotein purity of the purified recombinant protein was 98.6%, and the SDS electrophoresis diagram was shown. Figure 1 , showing an apparent molecular weight of 33.8 kDa, which is consistent with the results of recombinant batroxobin recorded in the literature (e.g. CN116286755B, 202310399963.2). The recombinant protein obtained after purification of the batroxobin fermentation concentrate obtained in step (6) of Examples 3, 5-6, and 8-9 also showed by SDS electrophoresis that its apparent molecular weight was in the range of 33.5-34.2 kDa, indicating that the products obtained in these experiments were consistent with the glycoprotein recombinant batroxobin.

[0064] Embodiment 10:According to the preparation process and operating parameters of Examples 7 to 9, respectively, but inositol was not added to the PTM1 solution used, three examples of preparing recombinant batroxobin were performed; when operating according to Example 7, the volume of the batroxobin fermentation concentrate obtained in step (6) was 2382 ml, the titer was 53.6 BU / ml, and the total titer was 127.7 kBU; when operating according to Example 8, the volume of the batroxobin fermentation concentrate obtained in step (6) was 2407 ml, the titer was 54.6 BU / ml, and the total titer was 131.4 kBU; when operating according to Example 9, the volume of the batroxobin fermentation concentrate obtained in step (6) was 2436 ml, the titer was 51.8 BU / ml, and the total titer was 126.2 kBU. These results show that when inositol is not added to the PTM1 solution, the expression level of recombinant batroxobin cannot be effectively increased.

[0065] Embodiment 11: According to the preparation process and operation parameters of Examples 7 to 9, respectively, but calcium pantothenate was not added to the PTM1 solution used, three examples of preparing recombinant batroxobin were performed; when operating according to Example 7, the volume of the batroxobin fermentation concentrate obtained in step (6) was 2426 ml, the titer was 60.7 BU / ml, and the total titer was 147.3 kBU; when operating according to Example 8, the volume of the batroxobin fermentation concentrate obtained in step (6) was 2374 ml, the titer was 59.4 BU / ml, and the total titer was 141.0 kBU; when operating according to Example 9, the volume of the batroxobin fermentation concentrate obtained in step (6) was 2403 ml, the titer was 60.6 BU / ml, and the total titer was 145.6 kBU. These results show that when calcium pantothenate is not added to the PTM1 solution, the expression level of recombinant batroxobin cannot be effectively increased.

[0066] Example 12: Effect of recombinant batroxobin on thrombosis It is known that natural batroxobin has anti-thrombotic effects. In this example, commercially available batroxobin injection (0.5 ml: 5BU) was used as a control, and the method of relevant literature (2010101577855) was referred to to investigate the effect of the purified recombinant batroxobin (glycoprotein purity of 98.6%) obtained in Example 7 of the present invention on venous thrombosis in healthy SD rats. The specific operation is as follows: 30 male healthy SD rats (Institute of Zoology, Chinese Academy of Sciences, SCXK (Beijing) 2021-0012, weighing 180-210g) were randomly divided into a blank control group, a batroxobin injection group, and a recombinant batroxobin group, with 10 rats in each group; the dose of the batroxobin injection group and the recombinant batroxobin group was 10BU / kg, the drug was diluted to an appropriate concentration with injection water, and 3ml / kg of the drug solution was injected intravenously, and the blank control group was injected with the same volume of 0.9% sodium chloride injection in the same way; after administration, the animals were anesthetized with sodium pentobarbital, fixed in a supine position, the skin was incised on the midline of the abdomen (about 2cm), the abdominal cavity was opened, the inferior vena cava was separated, and the inferior vena cava was ligated with No. 4 suture below the left renal vein, and the abdominal wall was sutured; after 3h, the abdominal cavity was reopened and the ligation was The blood vessel was clamped with an artery clamp about 2 cm below, the blood in the lumen of this section was sucked out, the vessel was cut open longitudinally, the thrombus was removed and its wet weight was weighed, and the wet thrombus was placed in a 40°C oven for 18 hours and then its dry weight was weighed; the results were expressed as mean ± sd, and the t-test was used for comparison among the groups. P < 0.05 indicated a significant difference; Results: The wet weight (mg) and dry weight (mg) of the blank control group were 15.46 ± 3.25 and 5.23 ± 2.14, respectively, the wet weight (mg) and dry weight (mg) of the batroxobin injection group were 4.73 ± 2.74** and 1.68 ± 1.47**, respectively, and the wet weight (mg) and dry weight (mg) of the recombinant batroxobin group were 4.48 ± 2.38** and 1.42 ± 1.19**, respectively, where ** indicates P < 0.01 compared with the blank control group. These results indicate that the recombinant purified batroxobin obtained in the present invention has an anti-thrombotic effect comparable to that of natural batroxobin. Although there is no statistical difference between the two, judging from the absolute value results alone, the recombinant batroxobin exhibits a better anti-thrombotic effect. If the production cost and resource availability are considered, it is obvious that the recombinant batroxobin obtained in the present invention has obvious industrial advantages over natural batroxobin.

[0067] The above is a detailed description of the spirit of the present invention through the preferred embodiments of the present invention. Those skilled in the art understand that any modification, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention fall within the protection scope of the present invention.

Claims

1. A method for preparing recombinant batroxobin, which comprises artificially synthesizing the structural gene sequence of batroxobin, then using Pichia pastoris to clone and express to obtain the seed solution of highly expressed engineered bacteria, and then fermenting and culturing to prepare recombinant batroxobin according to the following operations: (1) Preparation of primary seed solution: The selected engineered bacteria were inoculated into YPD medium and cultured in a shake flask until the OD600 reached 7-9, which was used as the primary seed solution; (2) Preparation of secondary seed solution: The primary seed solution was inoculated into YPD medium and cultured in a shake flask until the OD600 reached 7-9 to serve as the secondary seed solution; (3) Fermentation tank inoculation and pre-culture: The secondary seed liquid was inoculated into the fermentation medium of the fermentation tank, and cultured under the initial culture conditions of 30°C, pH 5.8-6.2, rotation speed 150-220 rpm, and air ventilation volume 0.8-1.2 vvm. During the fermentation process, the rotation speed and air ventilation volume were gradually increased, and the dissolved oxygen was controlled in the range of 15-25% until the rotation speed was increased to 650-750 rpm and the air ventilation volume was increased to 1.8-2.5 vvm. Then, the culture was continued until the carbon source was exhausted, and then glycerol fed-batch culture was carried out; (4) Glycerol feeding culture: Start feeding by adding 50% glycerol containing 10-14 ml / L of PTM1 solution at a rate of 5 ml / h / L. Gradually increase the feeding rate to 45-55 ml / h / L within 30 min. During this period, adjust the rotation speed and air ventilation volume to control the dissolved oxygen in the range of 15-25%. Continue to culture until the wet weight of the bacteria reaches the range of 250-270 g / L, and then enter the next methanol feeding; (5) Methanol feeding induction culture: the fermentation broth temperature was lowered to 25°C, the pH was adjusted to 2.8-3.2, and methanol containing 10-14 ml / L of PTM1 solution was added dropwise at a rate of 2.8-3.5 ml / h / L. The methanol feeding rate was maintained until the end of the fermentation. During this period, the rotation speed and air ventilation volume were adjusted to control the dissolved oxygen in the range of 15-25%. After the rotation speed and air ventilation volume reached the maximum, oxygen was introduced to achieve a maximum ventilation volume of 0.28-0.32 vvm. After the fermentation was completed, the fermentation broth was centrifuged and the supernatant was collected. (6) The centrifuged supernatant is ultrafiltered using an ultrafiltration membrane with a molecular weight cutoff of 10K, and concentrated until the volume of the liquid above the membrane is 1 / 10 of the volume of the initial supernatant to obtain a fermentation concentrate containing recombinant batroxobin, which is optionally purified.

2. The method according to claim 1, wherein the titer of the batroxobin fermentation concentrate obtained in step (6) is greater than 40BU / ml or greater than 80BU / ml.

3. The method according to claim 1, wherein: The composition of the YPD medium used was: 1% peptone, 0.5% yeast extract, 2% glucose, water, and hydrochloric acid or sodium hydroxide to adjust the pH to 6.0 ± 0.2; The composition of the fermentation medium used was: 85% phosphoric acid 13 ml / L, calcium sulfate dihydrate 0.46 g / L, potassium sulfate 9.1 g / L, magnesium sulfate heptahydrate 7.46 g / L, potassium hydroxide 2.06 g / L, glycerol 30.0 g / L, PTM1 solution 4.35 ml / L, and the balance water; The composition of the PTM1 solution used is: 6 g / L copper sulfate, 0.088 g / L sodium iodide, 3 g / L manganese sulfate, 0.2 g / L sodium molybdate, 0.02 g / L boric acid, 0.5 g / L cobalt chloride, 20 g / L zinc chloride, 65 g / L ferrous sulfate, 0.2 g / L biotin, and the balance water; or, The composition of the PTM1 solution used is: copper sulfate 6 g / L, sodium iodide 0.088 g / L, manganese sulfate 3 g / L, sodium molybdate 0.2 g / L, boric acid 0.02 g / L, cobalt chloride 0.5 g / L, zinc chloride 20 g / L, ferrous sulfate 65 g / L, biotin 0.2 g / L, inositol 1.2 g / L, calcium pantothenate 2.5 g / L, and the balance water.

4. The method according to claim 1, wherein when the structural gene sequence of batroxobin is artificially synthesized, in order to allow the synthesized target gene to be recombined into the yeast secretory expression vector pPICZα, an Xho I restriction site is added to the 5′ end of the gene, and a termination codon TAATGA and a SacII restriction site are added to the 3′ end of the gene.

5. The method according to claim 1, wherein when the structural gene sequence of batroxobin is artificially synthesized, the synthesized target gene and pPICZα vector are double-digested with Xho I and SacII, electrophoresed and recovered, the target gene is recombined into pPICZα, transformed into Escherichia coli Top10F', and screened; the Escherichia coli Top10F' transformed with pPICZα is cultured on an LB medium plate supplemented with Zeocin, a single colony is picked, cultured in a liquid medium, the plasmid is extracted, and double-digestion detection with Xho I and SacII, α-factor priming and 3'AOX1 priming PCR detection are performed, which shows that pPICZα contains the target gene and can be used to transform Pichia pastoris.

6. The method according to claim 1, wherein when the structural gene sequence of batroxobin is artificially synthesized, the LB medium with Zeocin added is composed of: 1% tryptone, 0.5% yeast extract, 0.5% sodium chloride, 1.5% agar, the pH value is adjusted to 7.0, autoclaved, and 25µg / mg zeocin is added during plating; the liquid culture medium: 1% tryptone, 0.5% yeast extract, 0.5% sodium chloride, the pH value is adjusted to 7.0, and autoclaved.

7. The method according to claim 1, wherein when Pichia pastoris is used for cloning expression screening to obtain the seed solution of highly expressed engineered bacteria, pPICZα-Bg is linearized with the DNA restriction endonuclease SacI-HF™, and a multi-copy Pichia pastoris expression kit of Gibco is used to prepare a yeast host competent state and transform it according to the method described in the kit, and the transformed cells are spread on YPDZ medium, grown at 30°C for 4 to 5 days to produce single colonies, and clones with large and full colonies are selected for expression screening, and highly expressed engineered bacteria are screened in test tubes and inoculated into shake flasks for proliferation as seed solution of engineered bacteria.

8. The method of claim 1, wherein: The YPDZ medium consists of: 1% yeast extract, 2% peptone, 2% glucose, 2% agar, and 200 µg / ml bleomycin; Step (1) Preparation of the primary seed solution: inoculate the selected high-expression engineered bacteria into a shake flask of YPD medium at an inoculum of 1‰, and culture at 30°C and 250rpm until the OD600 reaches 7-9, which is used as the primary seed solution; Step (2) Preparation of secondary seed solution: inoculate the primary seed solution in a shake flask of YPD medium at a 10% inoculum, and culture at 30°C and 250 rpm until the OD600 reaches 7-9, which is used as the secondary seed solution; In step (3), when the secondary seed liquid is inoculated into the fermentation medium of the fermenter, the volume ratio of the secondary seed liquid to the fermentation medium is 1:8-12; or, In step (5), while maintaining the methanol feeding rate until the end of fermentation, samples are taken at regular intervals to detect the expression level of the recombinant batroxobin in the supernatant, and when the expression level no longer increases, it is regarded as the end point of the fermentation.

9. Use of the recombinant batroxobin prepared by the method according to any one of claims 1 to 8 in the preparation of a medicament for the following medical indications: For acute cerebral infarction; Used to improve ischemic symptoms caused by occlusive vascular disease; Used to improve peripheral and microcirculation disorders.

10. The use according to claim 9, wherein the occlusive vascular disease is selected from the group consisting of thromboangiitis obliterans, deep vein thrombosis, and pulmonary embolism; and the peripheral and microcirculatory disorders are selected from the group consisting of sudden deafness and motion sickness.

Citation Information

Patent Citations

  • Batroxobin and its preparing process and specific coding gene

    CN100564532C

  • A recombinant batroxobin lyophilized formulation for thrombosis

    CN102258483B

  • Recombinant Anclozyme, its Industrial-Scale Preparation Method, and its Application in the Treatment of Acute Cerebral Infarction

    CN108559740B

  • Mixed carbon source induced pichia pastoris expression recombinant batroxobin and purification method thereof

    CN113862246A

  • Yeast fermentation culture medium

    CN116286408A